Media stories about ArQule (NASDAQ:ARQL) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ArQule earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.8208871514154 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Edited Transcript of ARQL earnings conference call or presentation 4-Aug-17 1:00pm GMT (finance.yahoo.com)
- ArQule, Inc. : Investor Network: ArQule, Inc. to Host Earnings Call (4-traders.com)
- ArQule’s (ARQL) CEO Paolo Pucci on Q2 2017 Results – Earnings Call Transcript (seekingalpha.com)
- ArQule Reports Second Quarter 2017 Financial Results (finance.yahoo.com)
- ArQule reports 2Q loss (finance.yahoo.com)
Separately, Zacks Investment Research cut shares of ArQule from a “hold” rating to a “sell” rating in a report on Thursday, May 4th.
ArQule (NASDAQ ARQL) traded down 1.82% on Tuesday, hitting $1.08. 82,514 shares of the company’s stock were exchanged. ArQule has a 12-month low of $0.92 and a 12-month high of $1.82. The company’s 50-day moving average price is $1.22 and its 200-day moving average price is $1.21. The company’s market cap is $76.84 million.
ArQule (NASDAQ:ARQL) last issued its earnings results on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. ArQule had a negative net margin of 482.44% and a negative return on equity of 116.26%. During the same period in the previous year, the business posted ($0.07) earnings per share. Analysts forecast that ArQule will post ($0.44) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “ArQule (NASDAQ:ARQL) Earning Somewhat Positive Media Coverage, Accern Reports” was originally published by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://baseballnewssource.com/markets/arqule-nasdaqarql-earning-somewhat-positive-media-coverage-accern-reports/1408459.html.
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with our FREE daily email newsletter.